Your browser doesn't support javascript.
loading
Leiomyosarcoma: Current Clinical Management and Future Horizons.
Devaud, Nicolas; Vornicova, Olga; Abdul Razak, Albiruni R; Khalili, Korosh; Demicco, Elizabeth G; Mitric, Cristina; Bernardini, Marcus Q; Gladdy, Rebecca A.
Affiliation
  • Devaud N; Instituto Oncologico Fundacion Arturo Lopez Perez (FALP), Santiago, Chile.
  • Vornicova O; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Abdul Razak AR; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Khalili K; Joint Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada.
  • Demicco EG; Department of Laboratory Medicine and Pathobiology, Sinai Health System, University of Toronto, Toronto, Ontario, Canada.
  • Mitric C; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Department of Obstetrics and Gynaecology, University of Toronto, Toronto, Ontario, Canada.
  • Bernardini MQ; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Department of Obstetrics and Gynaecology, University of Toronto, Toronto, Ontario, Canada.
  • Gladdy RA; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Division of General Surgery, Sinai Health System, University of Toronto, Toronto, Ontario, Canada. Electronic address: Rebecca.gladdy@sinaihealth.ca.
Surg Oncol Clin N Am ; 31(3): 527-546, 2022 07.
Article in En | MEDLINE | ID: mdl-35715148
ABSTRACT
Leiomyosarcomas are soft tissue tumors that are derived from smooth muscle mainly in the pelvis and retroperitoneum. Percutaneous biopsy is paramount to confirm diagnosis. Imaging is necessary to complete clinical staging. Multimodal treatment should be directed by expert sarcoma multidisciplinary teams that see a critical volume of these rare tumors. Surgery is the mainstay of curative intent treatment; however due to its high metastatic progression, there may be a benefit for neoadjuvant systemic treatment. Adjuvant systemic treatment has no proven disease-free survival, and its main role is in the palliative setting to potentially prolong overall survival.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sarcoma / Soft Tissue Neoplasms / Leiomyosarcoma Type of study: Diagnostic_studies Limits: Humans Language: En Journal: Surg Oncol Clin N Am Journal subject: NEOPLASIAS Year: 2022 Document type: Article Affiliation country: Chile Publication country: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sarcoma / Soft Tissue Neoplasms / Leiomyosarcoma Type of study: Diagnostic_studies Limits: Humans Language: En Journal: Surg Oncol Clin N Am Journal subject: NEOPLASIAS Year: 2022 Document type: Article Affiliation country: Chile Publication country: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA